Fixed-Dose Enoxaparin After Bariatric Surgery: The Influence of Body Weight on Peak Anti-Xa Levels

被引：0
|
作者：
Funda Celik
Alwin D. R. Huitema
Jan H. Hooijberg
Arnold W. J. M. van de Laar
Dees P. M. Brandjes
Victor E. A. Gerdes
机构：
[1] Slotervaart Hospital,Department of Internal Medicine, 9B
[2] Netherlands Cancer Institute,Department of Pharmacy & Pharmacology
[3] Slotervaart Hospital,Department of Clinical Chemistry and Hematology
[4] Slotervaart Hospital,Department of Surgery
[5] Academic Medical Center,Department of Vascular Medicine
来源：
Obesity Surgery | 2015年 / 25卷
关键词：
Anti-Xa levels; Obesity; Bariatric surgery;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：628 / 634
页数：6
相关论文
共 50 条
  • [1] Fixed-Dose Enoxaparin After Bariatric Surgery: The Influence of Body Weight on Peak Anti-Xa Levels
    Celik, Funda
    Huitema, Alwin D. R.
    Hooijberg, Jan H.
    van de Laar, Arnold W. J. M.
    Brandjes, Dees P. M.
    Gerdes, Victor E. A.
    [J]. OBESITY SURGERY, 2015, 25 (04) : 628 - 634
  • [2] Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery
    Kovacs, MJ
    Weir, K
    MacKinnon, K
    Keeney, M
    Brien, WF
    Cruickshank, MK
    [J]. THROMBOSIS RESEARCH, 1998, 91 (03) : 137 - 142
  • [3] Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin
    Rowan, Brea O.
    Kuhl, David A.
    Lee, Marilyn D.
    Tichansky, David S.
    Madan, Atul K.
    [J]. OBESITY SURGERY, 2008, 18 (02) : 162 - 166
  • [4] Anti-Xa Levels in Bariatric Surgery Patients Receiving Prophylactic Enoxaparin
    Brea O. Rowan
    David A. Kuhl
    Marilyn D. Lee
    David S. Tichansky
    Atul K. Madan
    [J]. Obesity Surgery, 2008, 18 : 162 - 166
  • [5] NADROPARIN AND ANTI-XA ACTIVITY AFTER BARIATRIC SURGERY
    Schijns, W.
    Aarts, E.
    Homan, J.
    Dogan, K.
    Betzel, B.
    Kaasjager, K.
    Janssen, I.
    Berends, F.
    [J]. OBESITY SURGERY, 2014, 24 (08) : 1259 - 1260
  • [6] NADROPARIN AND ANTI-XA ACTIVITY AFTER BARIATRIC SURGERY
    Schijns, Wendy
    Homan, Jens
    Aarts, Edo
    Dogan, Kemal
    Betzel, Bark
    Janssen, Ignace
    Deenen, Maarten
    Kaasjager, Karin
    Berends, F. J.
    [J]. OBESITY SURGERY, 2015, 25 : S52 - S52
  • [7] Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin
    Corinne Maurice-Dror
    Michael Litvak
    Anat Keren-Politansky
    Shanny Ackerman
    Nissim Haim
    Yona Nadir
    [J]. Journal of Thrombosis and Thrombolysis, 2020, 50 : 112 - 122
  • [8] Circulating heparan sulfate chains and body weight contribute to anti-Xa levels in cancer patients using the prophylactic dose of enoxaparin
    Maurice-Dror, Corinne
    Litvak, Michael
    Keren-Politansky, Anat
    Ackerman, Shanny
    Haim, Nissim
    Nadir, Yona
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2020, 50 (01) : 112 - 122
  • [9] Evaluation of Target Peak Anti-Xa Levels in Obese Patients Receiving Prophylactic Enoxaparin
    Marotto, Gina
    Namba, Jennifer
    Auger, William
    Tran, Vy
    [J]. CRITICAL CARE MEDICINE, 2013, 41 (12)
  • [10] Risk Stratification for Supratherapeutic Peak Anti-Xa Levels in Adult Patients on Therapeutic Enoxaparin
    Sheredy, Shane A.
    Stone, Andrew C.
    Mostafavifar, Ahmad M.
    Mostafavifar, Lisa G.
    Smith, Rachel M.
    Doepker, Bruce A.
    [J]. ANNALS OF PHARMACOTHERAPY, 2024, 58 (04) : 366 - 374
12345